Research
Hormonal
Intra-uterine levonorgestrel administration provides long-term symptom relief for symptomatic endometriosis, with pain and blood loss decreasing significantly over 3 years, though device retention rates drop over time due to irregular bleeding.
For symptomatic endometriosis, a Levonorgestrel IUD can significantly reduce pain and blood loss over 3 years. Be prepared for irregular bleeding in the first 6 months, which is the main reason women remove the device, but the long-term symptom relief is substantial.
ModerateQualifiesMEDIUM confidence
Symptom scores, assessed by a visual analog scale, showed a continuous decline up to 30 months and then a slight increase. ... Days of pain during a 28-day interval decreased significantly after 12 months and continued to decline, although at a slower rate. Total blood loss was significantly less after 12 months.
Why this rating
Prospective study, but small sample size (n=34) and high dropout rate (44% by 3 years).
Source
A Potential Decline in Life Expectancy in the United States in the 21st Century
S. Jay Olshansky et al. · Obstetrical & Gynecological Survey · 2005
DOI 10.1097/01.ogx.0000167407.83915.e7
narrative_reviewCited 1,949×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Microwave endometrial ablation (MEA) results in higher patient satisfaction and lower rates of subsequent hysterectomy compared to transcervical resection of the endometrium (TCRE) over a 5-year follow-up.Good
- Orlistat treatment for 3 months in women with PCOS produces a statistically significant reduction in body weight and serum testosterone levels, with weight loss effects being greater than those observed with metformin.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →